Biological Skin Substitutes Market To Reach $579.08 Million By 2030

Biological Skin Substitutes Market Growth & Trends

The global biological skin substitutes market size is expected to reach USD 579.08 million by 2030 and is expected to expand at a CAGR of 8.88% from 2025 to 2030 based on a new report by Grand View Research, Inc. The increasing prevalence of skin diseases, rising incidence of chronic diseases &   trauma emergencies, and increasing consciousness regarding tissue engineering, along with potential pipeline products, are some of the major factors responsible for the growth of tissue nano transfection technology. Furthermore, increasing government and private organizations’ investment in research and development activities is likely to boost the demand for biological skin substitutes.

The COVID-19 pandemic has affected several aspects of the wound care process, which includes compliance with wound care visits, triggering alternative approaches such as the use of virtual care platforms or telemedicine and streaming videos on the social media platform to assist the patients with wound dressing and empowering a do-it-yourself wound dressing approach. There is an increasing desire to understand how the social dimensions of health impact the Quality of Life (QoL) and effectiveness of wound care patients. The direct consequence of such changes in health care is the disruption of the continuity of wound care in several ways. However, these changes have negatively impacted wound outcomes but also have driven the development of a virtual-based approach for patient visits.

The key companies in the market are attempting to improve their portfolio by upgrading their products, employing significant cooperative efforts, and considering acquisitions and government permissions to increase their client base and capture a larger share of the biological skin substitutes market.

 Request a free sample copy or view report summary: Biological Skin Substitutes Market Report

Biological Skin Substitutes Market Report Highlights

• Based on type, the human donor tissue-derived products segment accounted for the largest market share of 67.42% in 2024 as it allows better integration and acceptance by the patient's body

• Based on application, the chronic wounds segment is expected to witness the fastest growth, with a CAGR of 9.13% over the forecast period due to the increasing prevalence of chronic wounds

• Based on end-use, the hospital segment dominated the biological skin substitutes market with a revenue share of 54.97% in 2024. The outpatient facilities segment is expected to witness the fastest CAGR of 8.9% over the forecast period owing to the shorter wait times and more flexible scheduling options

• North America accounted for the largest revenue share of nearly 41.25% in 2024 owing to the presence of major companies in the region

Biological Skin Substitutes Market Segmentation

Grand View Research has segmented the global biological skin substitute market report based on the type, application, end use, and region:

Biological Skin Substitute Type Outlook (Revenue, USD Million, 2018 - 2030)

• Human Donor Tissue-derived Products

• Acellular Animal-derived Products

Biological Skin Substitute Application Outlook (Revenue, USD Million, 2018 - 2030)

• Acute Wounds

• Chronic Wounds

Biological Skin Substitute End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Outpatient Facilities

• Research & Manufacturing

Biological Skin Substitute Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Biological Skin Substitute Market

• Organogenesis Inc.

• Integra LifeSciences Corporation

• Smith+Nephew

• Tissue Regenix

• MIMEDX Group, Inc.

• Essity Aktiebolag (publ))( Essity Health & Medical)

• Stryker

• Vericel Corporation

• 3M

• BioTissue